Scientific evaluation in the commercial assessment of early stage assets.

• An overview of how treatment of immune-mediated inflammatory diseases (IMIDs) is shifting towards targeted therapy and the implications this has for novel assets being explored in the category.
• The benefits of assessing the scientific appropriateness of an agent alongside an analysis of the treatment landscape, unmet needs in the area, and the competitive pipeline.
• A case study of Bryter’s approach to early stage market research in a highly competitive IMID category with a shifting treatment paradigm to targeted therapy aimed at specific patient phenotypes.

Fill in the form and we'll send your free download direct to your inbox

Learn more about how market research and insights can support in testing and development of new therapies and marketing strategies in our 'ultimate guide to pharmaceutical market research and insights'